- Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs.Publication without faculty affiliation
- RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors2017 | First Faculty of Medicine
- Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice2012 | First Faculty of Medicine
- Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs2012 | First Faculty of Medicine
- Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom2022 | First Faculty of Medicine
- Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU): The Phase 2 SATURN Study2019 | First Faculty of Medicine
- Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice2019 | First Faculty of Medicine
- Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries2011 | First Faculty of Medicine
- Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study2016 | First Faculty of Medicine
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions2013 | First Faculty of Medicine
- A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis2018 | First Faculty of Medicine
- The treatmentresistant depression - introduction to definition and classification2006 | Publication without faculty affiliation
- New treatment possibilities of homozygous familial hypercholesterolemia2023 | Faculty of Medicine in Hradec Králové
- Psoriatic arthritis news2019 | First Faculty of Medicine
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial2017 | Faculty of Medicine in Hradec Králové
- Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings2017 | First Faculty of Medicine
- Venous sinus stenting in idiopathic intracranial hypertension2020 | First Faculty of Medicine
- Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients2016 | First Faculty of Medicine
- Cost-Effectiveness of Hematopoietic Stem Cell Mobilization Strategies Including Plerixafor in Multiple Myeloma and Lymphoma Patients2013 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Clinial aspects of ASA resistance2017 | First Faculty of Medicine
- Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE2020 | First Faculty of Medicine
- Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis2017 | First Faculty of Medicine
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | First Faculty of Medicine
- The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma2019 | Second Faculty of Medicine
- Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis A Randomized Phase IIa Trial2015 | First Faculty of Medicine
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naive to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy2017 | First Faculty of Medicine
- Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration2018 | First Faculty of Medicine
- IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis2021 | Second Faculty of Medicine
- Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease2019 | First Faculty of Medicine, Central Library of Charles University
- Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial2023 | Publication without faculty affiliation